DL-dimyristoylphosphatidylglycerol

DL-Dimyristoylphosphatidylglycerol Overview

DL-dimyristoylphosphatidylglycerol (commonly abbreviated as DMPG) is a synthetic anionic phospholipid. Chemically, it belongs to the phosphatidylglycerols class within the glycerophospholipids superclass. Structurally, it features a glycerophosphoglycerol core esterified to two saturated 14-carbon fatty acid chains (myristic acid).

In clinical pharmacology, nanomedicine, and drug delivery systems, DMPG is classified as a pharmaceutical excipient, liposomal constituent, and solubilizing agent (ATC categories for lipids, membrane lipids, and glycerophospholipids). It is not an active therapeutic pharmaceutical ingredient and possesses no independent pharmacological disease indication. Instead, DMPG is utilized as a negatively charged structural lipid carrier in commercial liposomal and lipid-complex drug formulations such as the intravenous antifungal lipid complex Abelcet (Amphotericin B Lipid Complex) as well as in lipid nanoparticle (LNP) delivery vehicles. It is also widely used in biophysical research to study membrane dynamics and lipid-protein interactions.

What Is DL-Dimyristoylphosphatidylglycerol and How Does It Work?

DMPG is an amphiphilic, negatively charged (anionic) phospholipid that functions as a liposomal bilayer building block and solubilizing lipid matrix constituent.

Its primary chemical, physiological, and formulation mechanisms include:

• Self-Assembly into Lipid Matrices: DMPG contains a polar hydrophilic head group (glycerol-phosphate) and two non-polar hydrophobic fatty acid tails (myristoyl chains). In aqueous environments, it spontaneously self-assembles into spherical lipid bilayers (liposomes), lipid ribbon complexes, or micelles.
• Electrostatic Stabilization & Charge Dispersion: The negative charge of the glycerol-phosphate head group at physiological pH provides electrostatic repulsion between lipid particles. This prevents particle aggregation and flocs, stabilizing parenteral liposomal suspensions during storage and circulation.
• Drug Solubilization & Complexation: The hydrophobic core created by the saturated 14-carbon myristoyl chains traps hydrophobic or poorly soluble active drugs (such as Amphotericin B). The hydrophilic head groups face outward, maintaining high solubility and dispersion in blood.
• Reduction of Active Drug Toxicity: In lipid-complex formulations (such as Abelcet, which combines DMPG with dimyristoylphosphatidylcholine [DMPC] and Amphotericin B), binding the active drug to the lipid matrix alters systemic distribution. This lowers free drug exposure to renal tubular membranes, markedly reducing nephrotoxicity while preserving antimicrobial efficacy.
• Binding to Apolipoprotein E: Biophysical studies indicate that DMPG-containing lipid complexes bind to Apolipoprotein E, playing a role in lipoprotein-mediated clearance and cell membrane interactions.

Is DL-Dimyristoylphosphatidylglycerol FDA Approved?

Yes, DL-Dimyristoylphosphatidylglycerol is approved by the US FDA as an inactive pharmaceutical ingredient. It received its initial FDA clearance as an anionic liposomal structural lipid excipient in 1990s, within the approved prescription product Abelcet (Amphotericin B Lipid Complex Injection, NDA 050724). While it holds an active listing in the FDA Inactive Ingredient Database (IID) for intravenous formulations, it is not approved as a standalone active pharmaceutical drug because it possesses no intrinsic therapeutic activity.

What Is DL-Dimyristoylphosphatidylglycerol Used For?

• Anionic structural lipid constituent in parenteral liposomal and lipid-complex formulations to solubilize lipophilic active drugs (e.g., Amphotericin B Lipid Complex for severe invasive fungal infections).
• Excipient in lipid nanoparticle (LNP) systems to provide surface negative charge and prevent particle aggregation.
• Biophysical laboratory research reagent for constructing artificial lipid bilayers, vesicles, and model biological membranes.

Before Using Formulations Containing DMPG: Contraindications & Precautions

Do not administer DMPG-containing preparations if there is a documented severe hypersensitivity to DMPG, synthetic phosphatidylglycerols, or any active drug/excipient within the specific combination product (e.g., a severe allergy to Amphotericin B when using Abelcet). DMPG is an FDA-approved inactive pharmaceutical excipient and structural lipid carrier; it has no independent therapeutic activity.

Who Should Not Receive DMPG-Containing Formulations?

• Patients with a documented severe hypersensitivity to DMPG, synthetic phosphatidylglycerols, or any active drug/excipient within the specific combination product (e.g., severe allergy to Amphotericin B when receiving Abelcet).
• Specific contraindications are dictated entirely by the active pharmaceutical ingredient co-formulated with DMPG.

DMPG, Pregnancy & Fertility

DMPG is a synthetic analog of naturally occurring cell membrane phospholipids. As an inactive excipient, it undergoes normal metabolic degradation by endogenous phospholipases into fatty acids and glycerol. Pregnancy considerations, teratogenicity risks, and lactation safety depend strictly on the active pharmaceutical agent co-administered with DMPG.

Tell Your Doctor Before Receiving DMPG Formulations

Inform your physician if you have a history of severe allergies to liposomal products, lipid emulsions, or specific active drugs.

DMPG Dosage & Administration

DMPG has no standalone therapeutic dosage. Clinical dosing is governed entirely by the co-formulated active pharmaceutical ingredient within the lipid matrix. For example, in Abelcet Injection (which contains 1.5 mg DMPG and 3.4 mg DMPC per 5 mg Amphotericin B per mL), the standard adult and pediatric dosage for invasive fungal infections is 5 mg/kg of body weight daily via intravenous infusion.

Standard Dosing Guidelines

• Dosing is determined entirely by the active pharmaceutical agent formulated within the lipid matrix. DMPG itself has no separate therapeutic dose.
• Example (Abelcet Injection): Formulated with 1.5 mg DMPG and 3.4 mg DMPC per 5 mg Amphotericin B per mL. Standard adult and pediatric dosage for invasive fungal infections is 5 mg/kg of body weight administered intravenously once daily.

How DMPG Formulations Are Administered

• Administered strictly via the route specified by the co-formulated active drug (most commonly intravenous infusion).
• Parenteral lipid complexes must be diluted in compatible infusion fluids (such as 5% Dextrose Injection) according to strict manufacturer protocols. Do not mix with saline solutions or other medications that induce lipid precipitation.

Clinical Efficacy & Research

Biophysical and nanomedical research confirms that DMPG is a key structural lipid for parenteral drug delivery systems. The inclusion of an anionic lipid like DMPG alongside zwitterionic lipids (like DMPC) prevents vesicle fusion and maintains particle size stability. Clinical trials of DMPG-containing lipid complexes demonstrate that incorporating toxic lipophilic drugs (like Amphotericin B) into a DMPG/DMPC lipid ribbon matrix reduces treatment-limiting side effects (such as acute renal failure) while maintaining therapeutic tissue concentrations.

Side Effects & Safety Profile

As a non-toxic, biodegradable lipid, DMPG does not directly cause systemic toxicity. Side effects associated with DMPG-containing products are driven by the active drug or acute physical infusion reactions to lipid particles. Common infusion-related reactions include fever, chills, rigors, nausea, vomiting, mild transient hypotension, or flushing.

Common Side Effects

Side effects observed during infusion of DMPG-containing formulations are primarily driven by the active drug or acute physical infusion reactions to lipid nanoparticles:

• Systemic infusion reactions: Fever, chills, rigors, nausea, and vomiting during IV administration.
• Mild transient hypotension or flushing.

Serious Adverse Events

• Severe anaphylactic or anaphylactoid reactions to lipid complexes.
• Acute infusion-related hypoxia, bronchospasm, or severe back pain (pseudo-allergy / CARPA reactions associated with liposomal IV infusions).

Managing Side Effects

Infusion-related reactions to lipid formulations can often be managed by slowing the IV infusion rate and pre-medicating with antihistamines, acetaminophen, or low-dose corticosteroids.

Drug Interactions & What to Avoid

DMPG possesses no direct receptor-mediated chemical drug interactions; all clinical drug-drug interactions are dictated by the co-formulated active drug. Parenteral lipid complexes containing DMPG are physically incompatible with electrolyte-rich solutions (such as 0.9% Normal Saline) and can precipitate or undergo phase separation if mixed in the same IV line.

Drug Interactions

• DMPG does not possess direct receptor-mediated chemical drug interactions.
• Co-formulated active drugs determine all clinical drug-drug interactions.
• Physical Incompatibility: Liposomal and lipid-complex preparations containing DMPG can precipitate or break phase if mixed in the same IV line with electrolyte-dense solutions (like normal saline) or incompatible co-infused drugs.

Food & Alcohol

Systemic food and alcohol interactions are governed by the specific active drug co-administered with DMPG.

Overdose, Emergency & Storage

Because DMPG is an inactive lipid carrier, overdose management pertains strictly to the co-formulated active pharmaceutical ingredient, requiring immediate discontinuation of the infusion and supportive clinical care. Commercial products containing DMPG (e.g., Abelcet) must be stored under refrigeration between 2°C and 8°C (36°F to 46°F), protected from light and excessive heat, and never frozen.

Overdose Management

Because DMPG is a non-toxic lipid carrier, overdose concerns pertain strictly to the active pharmaceutical ingredient. Overdosage of lipid formulations requires supportive clinical care and immediate discontinuation of the infusion.

How to Store DMPG Formulations

Commercial drug products containing DMPG (like Abelcet) must be stored under refrigeration between 2 degrees C and 8 degrees C (36 degrees F to 46 degrees F). Do not freeze. Protect vials from light and excessive heat.

Patient Management & Monitoring

Laboratory and clinical monitoring protocols are dictated by the active drug (e.g., monitoring serum creatinine, BUN, electrolytes, and hepatic function during Abelcet therapy). Follow strict aseptic technique and specific dilution protocols during preparation. Regularly inspect lipid suspensions prior to infusion for phase separation or particulate matter, and manage mild infusion reactions by slowing the IV infusion rate or pre-medicating with antihistamines, acetaminophen, or low-dose corticosteroids.

Monitoring Protocols

• Laboratory and clinical monitoring are dictated by the active drug (e.g., monitoring serum creatinine, BUN, potassium, and liver function during lipid-complex antifungal therapy).

Key Clinical Do’s and Don’ts

• Do follow specific dilution and handling instructions for lipid-complex IV preparations.
• Do inspect lipid suspensions for phase separation or particulate matter prior to administration.
• Do not mix DMPG lipid infusions with saline or other drugs in the same IV line.

Frequently Asked Questions

References

• DrugBank Database – DL-Dimyristoylphosphatidylglycerol Profile (DB11284)
• Classyfire Database – Phosphatidylglycerols Chemical Taxonomy Profile

Legal Disclaimer

The detailed medical and chemical information provided on this specific web page is intended strictly for educational and informational purposes regarding complex pharmacological mechanisms. It absolutely does not constitute professional medical advice, medical diagnosis, or specific treatment recommendations. Always consult a licensed healthcare provider before making any personal decisions regarding complex medical conditions, medication adjustments, or dietary changes.